CDKN2A and neoplasm: Indeed, observation of less than 5% p16-positive tumor cells predicted a homozygous deletion of CDKN2A with a sensibility of 100%, a specificity of 71%, a positive predictive value of 50%, and a negative predictive value of 100% (Figure 3E).